达立多雷生用于治疗失眠
Daridorexant for the Treatment of Insomnia.
作者信息
Robinson Christopher L, Supra Rajesh, Downs Evan, Kataria Saurabh, Parker Katelyn, Kaye Alan D, Viswanath Omar, Urits Ivan
机构信息
Department of Anesthesiology, Beth Israel Deaconess Medical Center.
Georgetown University School of Medicine.
出版信息
Health Psychol Res. 2022 Aug 30;10(3):37400. doi: 10.52965/001c.37400. eCollection 2022.
PURPOSE OF REVIEW
Insomnia is a complex sleeping disorder that affects the lives of many individuals worldwide. Insomnia often occurs in the presence of coexisting comorbidities making it a complex disorder that requires a multifactorial approach to therapy. First-line therapy is cognitive-behavioral therapy for insomnia (CBT-I). Pharmacotherapy for insomnia falls into four classes based on mechanism of action: benzodiazepine receptor agonists (BZRAs), histamine receptor antagonists, melatonin receptor agonists, and dual orexin receptor antagonists (DORAs).
RECENT FINDINGS
Daridorexant is a dual orexin type 1 and types 2 (OX and OX) receptor antagonist that was recently approved by the US FDA for the treatment of adults suffering from insomnia. It was shown to be effective in reducing insomnia symptoms, increasing daytime functioning, and improving the overall quality of sleep. Daridorexant offers patients relief from insomnia while avoiding the severe side effects and dependency issues of traditional treatments like benzodiazepines and sedatives.
SUMMARY
In this article, we review the most recent data on insomnia treatments and summarize the safety and efficacy of daridorexant in treating insomnia.
综述目的
失眠是一种复杂的睡眠障碍，影响着全球许多人的生活。失眠常与其他共病同时存在，使其成为一种复杂的疾病，需要采用多因素治疗方法。一线治疗是失眠认知行为疗法（CBT-I）。失眠的药物治疗根据作用机制分为四类：苯二氮䓬受体激动剂（BZRAs）、组胺受体拮抗剂、褪黑素受体激动剂和双重食欲素受体拮抗剂（DORAs）。
最新发现
达立多雷克斯是一种双重食欲素1型和2型（OX1和OX2）受体拮抗剂，最近被美国食品药品监督管理局（FDA）批准用于治疗患有失眠的成年人。它被证明在减轻失眠症状、提高日间功能和改善整体睡眠质量方面有效。达立多雷克斯为患者缓解失眠，同时避免了苯二氮䓬类药物和镇静剂等传统治疗的严重副作用和依赖性问题。
总结
在本文中，我们回顾了失眠治疗的最新数据，并总结了达立多雷克斯治疗失眠的安全性和有效性。
Zotero 插件